Mucinous Adenocarcinoma of the Appendix: Grades, PMP, and Treatment
Mucinous adenocarcinoma of the appendix is a cancer of the mucus-making gland cells that line the appendix, with true invasion into the surrounding tissue. It is the most common gland-type cancer of the appendix. Unlike LAMN, it invades rather than pushes, and it is graded 1, 2, or 3. The 2025 consensus guidelines from the Peritoneal Surface Malignancy (PSM) Consortium base treatment on that grade and on whether the cancer has spread to the lining of the abdomen, where it can cause pseudomyxoma peritonei (PMP).
Mucinous adenocarcinoma of the appendix is one of the most confusing diagnoses in appendix cancer, because it sits close to two other terms people hear at the same time: LAMN and PMP. Many families are told all three words in the same week and are never shown how they fit together. We built this page to sort that out and to explain what the 2025 guidelines recommend at each grade.
The treatment sections follow the 2025 consensus guidelines from the PSM Consortium. More than 130 specialists, including surgeons, medical oncologists, pathologists, and patient advocates, voted on each step, and Dr. Michael Foote, who reviewed this page, is one of the authors. Sources are listed at the bottom.
What mucinous adenocarcinoma of the appendix is
Adenocarcinoma is cancer of gland cells. A mucinous adenocarcinoma is one that makes so much mucus that, under World Health Organization (WHO) rules, more than half of the tumor is made of extracellular mucin. To be called adenocarcinoma at all, the tumor must show true infiltrative invasion, meaning cancer cells dig into the tissue around them.
The 2025 guidelines estimate that mucinous adenocarcinoma makes up about 35 to 40 percent of gland-type (epithelial) cancers of the appendix, more than any other type. Counted against all appendix tumors, including neuroendocrine tumors, its share is smaller.
Mucinous adenocarcinoma, LAMN, HAMN, and PMP
These four terms describe related but different things:
| Term | What it describes |
|---|---|
| LAMN | A mucinous tumor in the appendix that pushes against the wall without invading, with low-grade cells. |
| HAMN | The same pushing growth as LAMN, but with high-grade cells. |
| Mucinous adenocarcinoma | A mucinous tumor that truly invades the surrounding tissue. Graded 1, 2, or 3. |
| PMP | Mucinous tumor that has spread inside the abdomen. It can come from LAMN, HAMN, or mucinous adenocarcinoma. |
The 2025 guidelines note that LAMN and HAMN, not adenocarcinoma, are the tumors most often responsible for PMP. In the past, some pathologists called any tumor that caused PMP an adenocarcinoma, so older reports can be misleading. The reverse also happens: when the disease in the abdomen is grade 2 or 3, the guidelines say the diagnosis is usually considered adenocarcinoma, even if the tumor in the appendix looked like a LAMN or HAMN, because the main disease is invasive. Expert pathology review is the way to get this right. The LAMN, HAMN, and PMP pages cover those diagnoses in detail.
The three grades of mucinous adenocarcinoma of the appendix
| Grade | Also called | What it means |
|---|---|---|
| Grade 1 (G1) | Well differentiated, low grade | Cells look close to normal and tend to grow slowly. |
| Grade 2 (G2) | Moderately differentiated | In between. Grade 2 is its own category and is not the same as grade 3. |
| Grade 3 (G3) | Poorly differentiated, high grade | Cells look very abnormal. Any signet ring cells place a tumor in grade 3. |
When the cancer spreads inside the abdomen, the disease there gets its own grade, called PMP grade 1, 2, or 3. The grade in the abdomen can differ from the grade in the appendix, and when it is higher, the disease in the abdomen guides treatment. Our post on why your appendix and your PMP can have different grades explains this. If signet ring cells are present, the signet ring cell carcinoma page applies too.
Tests after diagnosis
The 2025 guidelines recommend a history and physical exam; CEA, CA-125, and CA 19-9 blood tests, with CRP considered; CT or MRI; a colonoscopy; review of the tissue by an expert pathologist; and discussion at a multidisciplinary tumor board. Comprehensive genomic testing of the tumor should be considered, and germline testing for inherited cancer risk may be considered alongside family history.
Treatment when the cancer has not spread to the abdomen
Surgery
The guidelines recommend a right hemicolectomy, which removes the right side of the colon with its lymph nodes, for most mucinous adenocarcinomas. The exception is a well differentiated (grade 1) mucinous adenocarcinoma that is completely confined to the appendix, with clean margins and no concern for spread. In that case, a hemicolectomy may not add benefit, because lymph nodes are rarely involved. A 2026 study of 205 patients from a UK peritoneal center supports this. Cancer was found in the lymph nodes of about 1 percent of well differentiated mucinous adenocarcinomas, compared with about a third of moderately to poorly differentiated ones.
Chemotherapy
- Grade 1 (well differentiated) without spread: no evidence currently supports chemotherapy.
- Stage III (cancer in at least one lymph node), or stage II with high-risk features such as signet ring cells or less differentiated histology: the guidelines say to consider chemotherapy after surgery, usually FOLFOX or a stronger three-drug regimen, for 3 to 6 months with a goal of 6.
- Stage I or II without high-risk features: surveillance.
Treatment when mucinous adenocarcinoma has spread to the abdomen
Mucin only near the appendix
If the only disease outside the appendix is acellular mucin (mucin without tumor cells) near the appendix, the guidelines say the choice between observation and cytoreductive surgery depends on the estimated risk of the disease progressing. They note there is not yet enough evidence or agreement to recommend one approach for everyone, and that observation may be reasonable if everything was removed and there are no high-risk features.
Grade 1 disease in the abdomen
When complete removal looks possible, the guidelines recommend cytoreductive surgery (CRS) with intraperitoneal chemotherapy, such as heated chemotherapy (HIPEC), including a right hemicolectomy. A more limited bowel operation may be considered for well differentiated tumors if a hemicolectomy is not needed to remove everything. Chemotherapy through the vein has generally not been shown to help grade 1 disease, but it is recommended if the tumor in the appendix has high-risk features.
Grade 2 or grade 3 disease in the abdomen
The guidelines recommend both CRS and chemotherapy through the vein, with most experts preferring chemotherapy first to see how the cancer responds. Chemotherapy usually totals about 6 months. If complete removal still does not look possible after chemotherapy, the guidelines advise against CRS as a definitive treatment and point toward more chemotherapy, clinical trials, or supportive care. The medical centers and providers page lists centers with experience in this surgery.
Surveillance after mucinous adenocarcinoma of the appendix
Each visit includes a history and physical exam, CT or MRI of the chest, abdomen, and pelvis, and a CEA blood test plus any marker that was ever high. The 2025 guidelines recommend:
- No spread to the abdomen: every 3 to 6 months for 2 to 4 years, then once a year until 5 to 10 years.
- After treatment for grade 1 disease in the abdomen: every 6 months for 2 years, then yearly for 2 years, then every 2 years until 5 to 10 years.
- After treatment for grade 2 or 3 disease in the abdomen: every 3 months for 2 years, then every 6 months for 2 years, then yearly until 5 to 10 years, with ctDNA testing considered every 3 months for the first year.
The genetics of mucinous adenocarcinoma of the appendix
Genetics help explain why mucinous adenocarcinoma behaves differently from LAMN. In a small 2020 study that sequenced 10 mucinous adenocarcinomas, 7 carried a KRAS mutation, but only 1 carried a GNAS mutation, far fewer than in LAMN or HAMN. Half carried a TP53 mutation, and some had changes in genes such as PIK3CA, APC, and SMAD4 that were not seen in LAMN or HAMN. The 2025 guidelines note that tumors driven mainly by GNAS are less likely to respond to chemotherapy, and that TP53 changes are linked with higher-grade disease. They recommend genomic testing of the tumor for anyone whose cancer has spread. These studies are small, and pooling data from many patients is how the field will learn which treatments work for which tumors. That is why the Appendicure registry exists.
Add your mucinous adenocarcinoma data to the registry
The Appendicure Patient-Led Global Appendix Cancer Registry collects pathology, genomic, and molecular data from people with every appendiceal cancer type, including mucinous adenocarcinoma. It is IRB-reviewed, free, and open worldwide. Please use the form for where you live.
Already enrolled? Add new reports or correct your record.
Frequently asked questions about mucinous adenocarcinoma of the appendix
What is mucinous adenocarcinoma of the appendix?
It is a cancer of the mucus-making gland cells of the appendix that truly invades the surrounding tissue. More than half of the tumor is made of mucin. It is the most common gland-type cancer of the appendix.
Is mucinous adenocarcinoma the same as LAMN?
No. LAMN pushes against the appendix wall without invading it. Mucinous adenocarcinoma invades the surrounding tissue and is graded 1, 2, or 3.
Is mucinous adenocarcinoma the same as PMP?
No. PMP is mucinous tumor that has spread inside the abdomen. It most often comes from LAMN or HAMN, but mucinous adenocarcinoma can also cause it.
Do I need a right hemicolectomy for mucinous adenocarcinoma of the appendix?
For most people, yes. The 2025 PSM Consortium guidelines make one exception: a well differentiated (grade 1) mucinous adenocarcinoma completely confined to the appendix with clean margins.
Do I need chemotherapy for mucinous adenocarcinoma of the appendix?
It depends on grade and stage. No evidence supports chemotherapy for grade 1 disease without spread. Chemotherapy is considered after surgery for stage III or high-risk stage II disease, and recommended for grade 2 or 3 disease in the abdomen.
How long is follow-up after mucinous adenocarcinoma of the appendix?
Follow-up lasts 5 to 10 years, with scans and blood tests every 3 to 6 months at first. The exact schedule depends on whether the cancer spread to the abdomen and its grade there.
Related reading
- Appendiceal adenocarcinoma: mucinous and nonmucinous types
- LAMN cancer: low-grade appendiceal mucinous neoplasm explained
- Pseudomyxoma peritonei (PMP)
- Your appendix and your PMP can have different grades
- Signet ring cell carcinoma of the appendix
- What your surgeon should cover at your CRS/HIPEC consultation
Sources
- Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal tumors without peritoneal involvement. Cancer. 2025;131(13):e35867. doi.org/10.1002/cncr.35867
- Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvement. Cancer. 2025;131(13):e35874. doi.org/10.1002/cncr.35874
- Martin-Roman L, Larby L, Strach MC, et al. Evaluating the need for performing a right hemicolectomy in appendiceal adenocarcinomas. Eur J Surg Oncol. 2026;52(11):112090. doi.org/10.1016/j.ejso.2026.112090
- Liao X, Vavinskaya V, Sun K, et al. Mutation profile of high-grade appendiceal mucinous neoplasm. Histopathology. 2020;76(3):461-469. doi.org/10.1111/his.13986
- Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the PSOGI modified Delphi process. Am J Surg Pathol. 2016;40(1):14-26. doi.org/10.1097/PAS.0000000000000535
Medically reviewed by Michael Foote, MD, Medical Oncologist & Physician-Scientist, Memorial Sloan Kettering. This page was written with AI assistance. It is for education and does not replace advice from your own care team. Last updated November 2026.
